Caris Discovery
Unlock truly novel targets for your discovery pipeline
Caris has the tools and data to help you identify, develop and commercialize your next oncology targets.
Despite transformational breakthroughs in our understanding of disease, drug development has focused on a redundant, limited number of targets. Caris Discovery is an indication and modality-agnostic discovery engine which aims to identify and validate novel targets for therapeutic development using a portfolio of innovative tools and technologies:
- Interrogation of primary patient tissue
- Proprietary aptamer-based proteomic profiling platform (ADAPT)
- Unparalleled in silico analysis
- Cutting-edge research experimentation at Caris’ dedicated 59,000 square foot research lab
Harness the power of tissue-based discovery platforms and state-of-the art lab technologies to advance the next wave of therapeutics.
“Caris Discovery is uncovering novel unexplored targets in patient populations where precision therapeutics have yet to be developed.”
—Milan Radovich, PhD, Chief Scientific Officer
Broad Target Discovery Platform
Identify Novel Drug Targets
Tissue: Wet lab validation & characterization
Data: In silico validation & characterization
Machine Learning Predictive AI
State-of-the-Art Equipment and Facilities for Target ID and Therapeutic Development
- 50 NovaSeq Sequencers
- Largest NovaSeq sequencing lab in the U.S.
- Innovation for enhanced depth of coverage
- Maximal throughput and efficiency
Four Precision Medicine Laboratories (Phoenix and Dallas) Totaling 275,000+ Sq. FT
Clinical Blood Lab
(Cotton Center, Phoenix, AZ)
Clinical Tissue Lab
(Cotton Center, Phoenix, AZ)
Drug Target Discovery Lab
(Papago, Phoenix, AZ)
Coming Soon – Clinical Lab
(Irving, TX)
Flexible Partnering Structures to Accommodates Diverse Needs
Caris has developed a flexible partnering model to meet our partners specific needs. Whether it is a joint target discovery collaboration, target out-licensing or target validation model, Caris can structure partnerships to meet your needs.
Target Out-License
Internally discovered and fully validated novel targets
Joint Target Discovery
Partnering to jointly discover and develop therapeutic cancer targets
Target Validation
Collaborating together to validate drug targets
Discover
More
WES & WTS provide assurances to your clinical development programs with data-driven decisions.
Caris Life Sciences is at the forefront of a data-led revolution in personalized cancer care.
Get Answers from Caris Biopharma
"*" indicates required fields